Patrick Zarrinkar is a co-founder of Recludix Pharma and serves as President and Chief Scientific Officer. Dr. Zarrinkar has over 20 years of experience in drug discovery and technology development. He spent his early career at Ambit Biosciences, where he co-led the development and application of the KINOMEscan kinase profiling platform, now owned and marketed by DiscoverX/Eurofins, as well as the discovery and translational research of the FLT3 kinase inhibitor quizartinib. Dr. Zarrinkar was part of the founding scientific team at Blueprint Medicines and subsequently led drug discovery teams at Pfizer. Prior to co-founding Recludix, he was Vice President of Biology at Wellspring Biosciences where he worked on KRAS-G12C and menin inhibitors, including KO-539, currently in clinical development by Kura Oncology. Dr. Zarrinkar holds a Ph.D. in Biochemistry from MIT.
« Go Back